Publications by authors named "Spinuzza A"
Growth in Children With Noonan Syndrome and Effects of Growth Hormone Treatment on Adult Height.
Front Endocrinol (Lausanne)
February 2022
Article Synopsis
- - The study focused on evaluating how rhGH treatment affects growth and adult height in children with Noonan syndrome (NS), particularly those with growth hormone deficiency (GHD).
- - Researchers analyzed data from 228 NS patients over key ages, finding that rhGH treatment significantly improved height standard deviation scores, leading to height gains during treatment.
- - Despite the improvement, there were no notable differences in height measurements between treated and untreated patients at adult height; further research is suggested to understand genotype-specific responses to rhGH.
Background: Children with nonclassical congenital adrenal hyperplasia (NCCAH) often present increased growth velocity secondary to elevation of adrenal androgens that accelerates bone maturation and might compromise adult height (AH).
Objective: The aim of the study was to analyze prognostic factors affecting growth trajectory (GT) and AH in children with NCCAH.
Methods: The study was a retrospective, multicentric study.
Omalizumab is a monoclonal antibody, targeting Fc receptor of IgE, approved for the treatment of allergic asthma and chronic spontaneous urticaria. Its utility in atopic dermatitis appears controversial from data in literature since the molecule is well tolerated but it seems less effective than other medications used in adult patients (eg, Dupilumab). At present, the use of Dupilumab is not approved in pediatric patients therefore there are no second level treatments available in this age group.
View Article and Find Full Text PDFHenoch Schonlein Purpura (HSP) is a systematic IgA-mediated vasculitic disease that affects the small vessels of the skin, the joints, the gastrointestinal tract and the kidneys (1). It is the most common childhood vaculitis, with an incidence estimated at 3-26 per 100,000 children, and with a male-to-female ratio of 2:1 (2-6). The 90% of patients are under 10 years of age, with a mean age of 4 years (4).
View Article and Find Full Text PDFNocturnal enuresis (NE) was defined by the World Health Organization (ICD-10) and the American Psychiatric Association (DSM-5) as bed-wetting in children aged >5 years. In cases of mental retardation, the developmental age may be equivalent to 5 years. In this review, we focus on the current knowledge about the etiology of enuresis and the most recent therapeutical options.
View Article and Find Full Text PDFBackground: High mobility group box 1 (HMGB1) is abnormally expressed in serum and sputum of patients with allergic asthma.
Objective: The aim of this study was to investigate the role of HMGB1 as guidance for treatment management of children with asthma.
Methods: Thirty children with asthma and 44 healthy children were enrolled.